SEC Form 4 · accession 0001209191-17-055737
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Davidson
Officer — Chief Medical Officer
Period of report
Oct 2, 2017
Accepted (ET)
Oct 4, 2017 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 2, 2017 | M | 4,000 | $5.5004 | A | 19,977 | D | |
| Common StockF2 | Oct 2, 2017 | S | 1,341 | $130.373 | D | 18,636 | D | |
| Common StockF3 | Oct 2, 2017 | S | 2,459 | $131.7524 | D | 16,177 | D | |
| Common Stock | Oct 2, 2017 | S | 200 | $132.20 | D | 15,977 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $5.5004 | Oct 2, 2017 | M | 4,000 | D | — | Jan 16, 2023 | Common Stock | 4,000 | 87,151 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016.
- F2The range of prices for the transaction reported on this line was $130.00 to $130.75. The average weighted price was $130.3730. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The range of prices for the transaction reported on this line was $131.05 to $132.00. The average weighted price was $131.7524. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.